5th Targeted Radiopharmaceuticals Summit US On 21 Jul to 23 Jul 2026

Maximizing the Potential of Radiopharmaceuticals through Novel Targets, Expanded Isotopes and Supply, and Enhanced Dosimetry to Drive Efficacious Therapies From Bench to Approval.
 
Radiopharmaceuticals are no longer an emerging promise, they are becoming a defining force in oncology. Once considered a niche modality, targeted radiopharmaceutical therapies are rapidly moving into the spotlight as one of the most promising approaches for precision cancer treatment. With major pharmaceutical companies investing heavily, pipelines expanding at pace, and clinical successes demonstrating the power of targeted radiation delivery, the field is transitioning from early validation to scale.
 
Momentum across the sector is undeniable. Breakthrough therapies continue to advance through the clinic, alpha-emitting isotopes are unlocking new possibilities for highly potent tumour targeting, and the theranostic paradigm is redefining how patients are diagnosed and treated. As more assets progress into late-stage trials and combination strategies gain traction, radiopharmaceuticals are positioned to play a central role in the next generation of oncology therapeutics.
 
Yet with this rapid growth comes a unique and complex set of challenges. Unlike traditional drug modalities, radiopharmaceutical development requires a tightly integrated ecosystem spanning isotope production, radiochemistry, manufacturing infrastructure, specialized clinical sites, and regulatory expertise.
 
This is why the 5th Targeted Radiopharmaceuticals Summit US returns in 2026 as the industry's most comprehensive end-to-end meeting dedicated to advancing radioligand therapies from discovery through to commercialization. Taking place July 21–23, 2026 in San Diego, California, the summit will bring together 260+ leaders from across the radiopharmaceutical field, including biopharma innovators, nuclear medicine physicians, radiochemists, isotope suppliers, CDMOs, regulators, and investors, to tackle the scientific, clinical, and operational challenges shaping the field.
 
Over three days of technical discussions, strategic insights, and collaborative networking, attendees will explore the full lifecycle of targeted radiopharmaceutical development, from discovery and preclinical innovation through clinical translation, manufacturing scale-up, and supply chain resilience.
 
Whether you are developing the next generation of radioligand therapies, building isotope production capacity, advancing clinical trials, or supporting the infrastructure needed to bring these therapies to patients, the 5th Targeted Radiopharmaceuticals Summit US is where the community comes together to move the field forward. Join the experts shaping the future of targeted radioligand therapy and help define the next chapter of precision oncology.